Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant

Welcome to Dwaey, specifically on Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant page.
This medicine contains important and useful components, as it consists of
Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant is available in the market in concentration.

Generic Name of Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant - Learn More

Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant

Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant Precaution - What You Need to Know

Before receiving the HPV Bivalent Vaccine (Types 16 and 18), it is crucial to consult a healthcare provider to ensure it is appropriate for the individual’s health condition. Important precautions include:

- Allergic Reactions: Individuals with a known allergy to any component of the vaccine, especially yeast, should avoid the vaccine. Allergic reactions, such as hives, swelling, or difficulty breathing, should be promptly addressed if they occur after administration.
- Pregnancy: The vaccine is not recommended for use during pregnancy unless clearly needed. However, if the vaccine is given during pregnancy, no specific adverse effects have been reported. Pregnant women should consult their healthcare provider before vaccination.
- Immunocompromised States: Patients with weakened immune systems, including those undergoing chemotherapy or taking immunosuppressive drugs, may not respond as effectively to the vaccine. The vaccine can still be given, but its efficacy might be lower.
- Fainting: As with any vaccine, some individuals (especially adolescents) may experience fainting or dizziness after receiving the vaccine. It is recommended to remain seated or lying down for 15 minutes post-injection to avoid injury from fainting.
- Autoimmune Conditions: Individuals with autoimmune disorders should inform their healthcare provider before vaccination as there is a need for careful evaluation of potential risks.

Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant Indication - Uses and Benefits

The HPV Bivalent Vaccine (Types 16 and 18) is primarily indicated for the prevention of diseases associated with the Human Papillomavirus (HPV), particularly types 16 and 18, which are known to cause various cancers and lesions:

- Cervical Cancer: This vaccine prevents infection with HPV types 16 and 18, which are responsible for approximately 70% of cervical cancers worldwide.
- Precancerous Cervical Lesions: It helps in the prevention of precancerous cervical lesions (CIN) caused by these HPV types.
- Genital Warts: While the bivalent vaccine mainly targets types 16 and 18, it may provide some protection against the development of genital warts, which are often caused by other HPV types.
- Other HPV-related Cancers: It can also provide protection against HPV-associated anal, oropharyngeal, and vulvar cancers.

Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant Contraindications - Important Warnings

The HPV Bivalent Vaccine should not be administered in the following cases:

- Allergy to Vaccine Components: If an individual has had a severe allergic reaction to yeast or any component of the vaccine, it should be avoided.
- Pregnancy: The vaccine is not recommended during pregnancy. While it is not known to cause harm if given by mistake during pregnancy, it is better to delay vaccination until after childbirth.
- Severe Illness: Patients with acute illnesses should wait until they recover before receiving the vaccine. Mild illnesses like a cold are not contraindications.
- Severe Immunodeficiency: People with severe immunosuppression, such as those receiving chemotherapy or with uncontrolled HIV, may have a reduced immune response to the vaccine and should discuss the decision with their healthcare provider.

Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant Side Effects - What to Expect

The HPV Bivalent Vaccine is generally well-tolerated, but like any vaccine, it may cause some side effects:

- Common Side Effects:
- Pain, swelling, or redness at the injection site.
- Fever.
- Fatigue or headache.
- Nausea.
- Dizziness or fainting, especially in adolescents. It is recommended to stay seated for 15 minutes after the vaccination to reduce the risk of fainting.

- Serious Side Effects (rare):
- Severe allergic reactions (e.g., anaphylaxis) with symptoms such as difficulty breathing, swelling, or hives.
- Guillain-Barré syndrome: A rare condition that can cause muscle weakness or paralysis.
- Blood clots: Although rare, some cases of blood clots have been reported after vaccination. It is crucial to discuss any concerns with a healthcare provider, especially if there is a personal history of blood clotting disorders.

Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant Pregnancy Category ID - Safety Information

2

Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant Mode of Action - How It Works

The HPV Bivalent Vaccine (Types 16 and 18) works by stimulating the immune system to produce antibodies against the virus. Here's how it functions:

- Viral-Like Particles (VLPs): The vaccine contains recombinant HPV VLPs, which mimic the surface proteins of the HPV virus but do not contain the live virus. These particles are made from the L1 protein of HPV types 16 and 18.
- Immune Response Activation: When the VLPs are introduced into the body, the immune system recognizes them as foreign invaders, prompting the production of neutralizing antibodies. These antibodies help prevent HPV infection in the future by targeting and neutralizing the virus before it can infect cells.
- Long-Term Protection: The vaccine induces a strong immune response that provides protection against HPV-related diseases for at least 10 years, with the possibility of longer-lasting immunity.

Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant Drug Interactions - What to Avoid

The HPV Bivalent Vaccine may interact with other vaccines and treatments:

- Other Vaccines: The vaccine can generally be co-administered with other routine vaccines, such as the meningococcal, hepatitis B, or influenza vaccines. It should be given at separate injection sites. It is essential to follow the recommended vaccine schedules.
- Immunosuppressive Drugs: If the patient is undergoing immunosuppressive treatment (e.g., steroids, chemotherapy), the immune response to the vaccine might be weakened, reducing its effectiveness.
- Blood Products: If the individual has recently received blood products or immunoglobulins, there may be a need to delay vaccination, as these products can interfere with the vaccine’s effectiveness.

Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant Pregnancy Category Note - Key Information

Pregnancy category: B; Not recommended for use in pregnant women



Women who become pregnant after initiating the vaccination series, no intervention is needed; delay the remaining doses until completion of pregnancy

Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant Adult Dose - Recommended Dosage

The HPV Bivalent Vaccine is administered as a 3-dose series for adults:

- First Dose: Given at the chosen time.
- Second Dose: Administered 1-2 months after the first dose.
- Third Dose: Given 6 months after the first dose.

This schedule is recommended for adults up to 45 years of age. The vaccine should be administered as soon as possible, especially before the individual becomes sexually active, for the best protection against HPV-related diseases.

Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant Child Dose - Dosage for Children

For children and adolescents, the HPV Bivalent Vaccine is given as a 2-dose series for those aged 9–14 years:

- First Dose: Given at the start of the vaccination series.
- Second Dose: Administered 6–12 months after the first dose.

If the vaccination is initiated after age 15, the 3-dose series should be followed to ensure optimal protection. The vaccine is recommended to be administered before any potential sexual activity for the best preventative outcome.

---

Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant Renal Dose - Dosage for Kidney Conditions

No dosage adjustment is needed for patients with renal impairment. The HPV Bivalent Vaccine is safe for individuals with mild to moderate kidney disease. However, those with severe renal dysfunction should consult their healthcare provider prior to vaccination to assess individual suitability.